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improvement since 2007. Methods: To determine the impact of HER2 testing quality 
improvement over years, we used a standardized 5-step methodology: 1) thesis state-
ment of the purpose of the project and the criteria to measure the value of an offer, 2) 
decision tree, 3) patient flow, 4) cost evaluation, 5) communication to stakeholders. For 
HER2 testing, considering costs and life saved as outcomes, we built a decision tree in 
order to describe the patient flow of patients diagnosed with breast cancer according 
to HER2 testing and treatment patterns. Two simulations were conducted for year 2007 
and 2014 according to HER2 testing improvement. Testing costs, medical staff and 
supply costs were considered. Results: Yearly, more than 48,700 malignant breast 
cancers (in situ not included) are diagnosed in France. In 2007 HER2 testing errors 
varied between 10% to 17% for false positive and between 4% to 8% for false negative 
respectively. These rates declined in 2014 to 7%-10% for false positive and 2%-4% for 
false negative respectively. This improvement of HER2 testing quality resulted in more 
patients receiving Herceptin at adjuvant stage. Consequently, over the 7 last years this 
led to annual increase of around 160-330 lives saved and a global increase of € 10M for 
drug spending. ConClusions: As targeted therapies’ offer increases more and more 
in cancer treatment, besides treatment efficacy, it appears crucial to continue opti-
mizing patients profiling with performant testings relying on national quality control 
insurance. Education, recommendations and good practices workflow are mandatory
PMD165
UniqUe Device iDentifier SySteM: the iMPact Of the POrtUgUeSe 
exPerience
alves Da Silva E, Figueira J, J 
INFARMED_ National Authority for Medicines and health Products, Lisboa, Portugal
objeCtives: The Portuguese National Health System (NHS) identified the need to 
easily access information that allowed identification of all medical devices (MDs) 
with their respective manufacturers, distributors, characteristics, and purposes. 
The objective of the creation of an information system is to collect, store and ana-
lyze data of each MD and to provide NHS resources management, health technol-
ogy assessment (HTA), as well as data about the Portuguese market. Methods: 
METHODS A system consisting of a database that is a repository, and an application 
system that stores the information was built. For the registry of information all MDs 
should disclose their respective instructions of use, labels and price. The concept of 
unique medical device and a process to assign a code to each device was designed, 
and tested by collecting data from NHS acquisitions. The prescription of medical 
devices is made by code (unique device identifier), with all information online. 
A model for communication between the health regulatory agency and market 
operators was also devised, as well as rules and codes of procedure. Results: The 
creation of this system in 2011 allowed for the coding of 44% of all registered MDs 
(n= 1000000) up to June 2015. This has allowed for the elimination or withdrawal 
of 21% (n= 215000) of references, thus keeping the registries up to date. The coding 
(unique device identifier), permitted the comparison of devices and the manage-
ment of total expenditure in MDs by hospitals of the NHS. ConClusions: The 
system provides solid information about available MDs in the market, their respec-
tive manufacturer, distributor and pricing to which they are sold to the NHS. The 
system is a support for decision makers, payers, and HTA processes. It facilitates 
the management and traceability of medical devices in hospitals and has impact 
on reimbursement, access and pricing varies by market
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objeCtives: There have been recent concerns about the association of ulcer-healing 
medications, including proton pump inhibitors (PPIs) with ischemic heart disease 
(IHD), including heart attacks. This issue has brought about media attention and 
could have implications on patient care in real-world settings. This pharmacovigi-
lance analysis aims to detect signals of IHD in patients treated with PPIs. Methods: 
Adverse event reports submitted to the FDA Adverse Event Reporting System were 
used (cumulative to June 2014), and Multi-item Gamma Poisson Shrinker dispro-
portionality analysis algorithm was applied to calculate Empirical Bayes Geometric 
Mean (EBGM) and corresponding 95%CI (EB05-EB95) as association metrics. PPIs 
were defined by generic names, and IHD events were defined as structured MedDRA 
queries of Preferred Terms denoting to IHD. Safety signals were defined as drug-
event associations with EB05≥ 2.0. Signal detection of myocardial infarction (MI) 
was conducted as sensitivity analysis. Results: There were 1,731 cases of IHD 
reported for PPIs; of those, 74% (n= 1,279) were for MI. 52% of IHD reports were 
females (mean age= 63 years); 75% were from the US; 93% were reported by PPIs 
manufacturers within 15 days of IHD occurrence. 96% of reported IHD events were 
serious, corresponding to 13% fatalities; 7% life-threatening events; 50% required 
hospitalization; 6% disabilities; and 2% required medical intervention. Healthcare 
professionals and consumers contributed to 13% and 4% of reported IHD events, 
respectively. No disproportional reporting of IHD (EBGM= 0.74; EB05-EB95= 0.72-0.77) 
nor MI (EBGM= 0.69; EB05-EB95= 0.66-0.72) was found for PPIs. 57% of IHD cases 
had previous and concurrent treatment with cardiovascular medications (mean= 3 
medications per report). ConClusions: Ulcer-healing treatment with PPIs is not 
associated with IHD, and protopathic bias could have contributed to the observed 
casual association in published studies, where PPIs could have been prescribed 
to treat gastric prodromal symptoms of MI. Pharmacoepidemiologic studies are 
required to further evaluate the impact of this bias.
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objeCtives: The purpose of this study was to evaluate whether F-18 fluoromisoni-
dazole PET or PET/CT (FMISO) was safe and effective for malignant tumor patients 
and to determine a possibility of the introduction in Korea reimbursement regula-
tion. Methods: A systematic literature review was used to evaluate the safety and 
effectiveness for FMISO. The 27 articles were selected and two reviewers evaluated 
independently the quality of these selected articles using the Scottish Intercollegiate 
Guidelines Network (SIGN) tool. Results: The correlation between tumor hypoxic 
imaging via FMISO and tumor imaging using existing imaging tests for diagnosing 
tumors in 14 articles was almost weak. By evaluating the hypoxic tumor lesions 
via FMISO, it was able to plan an intense radiotherapy that irradiate high dose in 
hypoxic area and to determine the therapeutic response and prognosis in 15 arti-
cles. ConClusions: The FMISO supplement the information of the heterogene-
ous tumor microenvironment as an add-on test and is a safe and effective test to 
determine the treatment direction through dose planning, prognosis, checking of 
therapeutic response for malignant cancer patients. Based on this evidence, FMISO 
will be introduced to the market within reimbursement regulation.
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objeCtives: The purpose of this study was to explore the effectiveness of thermodi-
lution technique method for vascular access flow measurement for the patients 
with hemodialysis were assessed. Methods: A systematic review was conducted to 
identify relevant articles published until May 4, 2015. Ovid-MEDLINE, Ovid-EMBASE, 
The Cochrane Library and the international databases of health technology agen-
cies were searched using the term ‘thermodilution technique method’. The SIGN 
(Scottish Intercollegiate Guidelines Network) methodology checklists were used for 
critical appraisal. Two review authors independently applied the extracted data and 
assessed the study quality. After data extraction, descriptive analysis was carried 
out. Results: A total of 12 literatures were included in the final assessment by 
applying our inclusion criteria. As the result of systematic reivew, the correlation of 
thermodilution techinique metohd and saline dilution method obtained excellent 
correlation. Statistically significant differences were obtained in patients age (> 65 
years old) and peripheral vascular disease were associated with a significantly lower 
flow access. Reproducibility of thermodilution technique method and saline dilution 
method, expressed as relative differences, was significantly different from saline 
method. ConClusions: Based on the current findings, we concluded that ther-
modilution technique method is effectiveness technology when used on patients 
with hemodialysis.
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objeCtives: This study analysed the National Institute of Health and Care 
Excellence’s (NICE) Medical Technology Evaluation Programme (MTEP) to identify the 
drivers of decisions for medical devices. Methods: All published MTEP appraisals 
were reviewed to capture data on the quality of submissions and outcomes, using a 
pre-designed data-extraction form. Results were analysed descriptively. Results: 
24 MTEP decisions are publically available. It was unclear if all submissions included 
a systematic literature review (SLR) as this was not routinely referenced. The clinical 
evidence submitted varied from unpublished observational data, to twenty-eight 
studies identified through a SLR, with a typical submission including three to twelve 
studies. Similarly, the complexity of economic evidence submitted varied; 87.5% con-
ducted cost-analyses or decision-trees, while 12.5% conducted Markov models. 75% 
of appraisals were positive, with NICE concluding that the technology was equally or 
more effective, and cost-saving or neutral compared to current care. In 66% of positive 
decisions, NICE noted the lack of robust clinical evidence. NICE accepted the results of 
observational studies and case-studies, particularly when randomised clinical trials 
were uncommon in a therapeutic area. In 28% of positive decisions, NICE disputed 
the model assumptions and revised the results but accepted the conclusions if cost-
savings were still demonstrated. In contrast, the rationale for all negative decisions 
was a lack of clinical evidence. In more than half of negative appraisals, NICE referred 
to the quality of the submission, noting that the SLR included studies out of scope 
or missed relevant studies or the submission relied heavily on poor quality studies. 
In all negative decisions, NICE encouraged further research. ConClusions: A NICE 
MTEP submission is likely to result in a positive decision, if evidence collection is 
well-conducted, and the device demonstrates equivocal or better effectiveness and 
cost savings compared to standard care, even if limited clinical trials are available.
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objeCtives: For HER2+ breast cancer patients, initiating the adapted treatment at 
an early stage increases the chance of survival. Between 2007 and 2014, quality of 
HER2 testing improved significantly, leading to lower rates of error on HER2 status. 
We developped a model to evaluate the public health impact of HER2 testing quality 
